Loading
A phase 3 trial of Triptorelin in Prostate cancer, run by Ipsen, completed.
Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer is a phase 3 interventional study registered as NCT01020448 by Ipsen, with 339 participants recorded, started 2009-11 and reaching its primary completion in 2011-11. Interventions recorded: Triptorelin (Decapeptyl®). Conditions recorded: Prostate Cancer.
Linked to the drug Triptorelin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Triptorelin, Prostate cancer and the tag pipeline.
Shares Ipsen and the tag pipeline.
Shares Ipsen and the tag pipeline.
Shares Ipsen and the tag pipeline.
Shares Ipsen and the tag pipeline.
Shares Triptorelin and the tag pipeline.
Shares Ipsen and the tag pipeline.
Shares Triptorelin and the tag pipeline.